Should I buy or sell Heron Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HRTX shares. View HRTX analyst ratings or view top-rated stocks .

What is Heron Therapeutics' stock price target for 2024?

3 brokers have issued 1-year target prices for Heron Therapeutics' shares. Their HRTX share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 386.1% from the stock's current price. View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts .

How have HRTX shares performed in 2023?

Heron Therapeutics' stock was trading at $2.50 at the start of the year. Since then, HRTX shares have decreased by 42.4% and is now trading at $1.44. View the best growth stocks for 2023 here .

When is Heron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our HRTX earnings forecast .

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08. The biotechnology company had revenue of $30 million for the quarter, compared to the consensus estimate of $27.24 million. Heron Therapeutics had a negative net margin of 97.45% and a negative trailing twelve-month return on equity of 21,127.62%. The company's revenue was up 44.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.54) EPS.

What ETFs hold Heron Therapeutics' stock?

ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Invesco Nasdaq Future Gen 200 ETF (QQQS) . Simplify Propel Opportunities ETF (SURI) .

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU) , Pfizer (PFE) , Gilead Sciences (GILD) , Sorrento Therapeutics (SRNE) , NVIDIA (NVDA) , Editas Medicine (EDIT) , Immunomedics (IMMU) , bluebird bio (BLUE) , AT&T (T) and Amarin (AMRN) .

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Rubric Capital Management LP (18.98%), JW Asset Management LLC (1.71%), Tejara Capital Ltd (1.50%), Tejara Capital Ltd (1.50%), Adage Capital Partners GP L.L.C. (1.42%) and New York State Common Retirement Fund (0.78%). Insiders that own company stock include Adam Morgan, Craig A Collard, Craig A Johnson , David Leslie Szekeres, Ira Duarte, Kimberly Manhard , Waage Christian and William P Forbes. View institutional ownership trends .

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Heron Therapeutics have any subsidiaries?

The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V.. Read More

Heron Therapeutics Stock Price, News & Analysis (NASDAQ:HRTX)

$1.44

-0.01 (-0.69%)

(As of 12/6/2023 ET)

Compare

Today's Range: $1.43
▼
$1.52
50-Day Range: $0.54
▼
$1.50
52-Week Range: $0.50
▼
$3.41

Volume: 2.11 million shs
Average Volume: 2.35 million shs
Market Capitalization: $216.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Heron Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 386.1% Upside
$7.00 Price Target
Short Interest: Bearish
11.72% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.96
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$260,650 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.88) to ($0.39) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

205th out of 955 stocks

Pharmaceutical Preparations Industry

66th out of 400 stocks

3.5

Analyst's Opinion

Consensus Rating
Heron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Heron Therapeutics has a forecasted upside of 386.1% from its current price of $1.44.
Amount of Analyst Coverage
Heron Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
11.72% of the outstanding shares of Heron Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Heron Therapeutics has a short interest ratio ("days to cover") of 6.4.
Change versus previous month
Short interest in Heron Therapeutics has recently decreased by 4.45%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Heron Therapeutics does not currently pay a dividend.
Dividend Growth
Heron Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Heron Therapeutics has received a 61.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Antiemetics and antinauseants (A04)", "Bupivacaine", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Heron Therapeutics is -1.96.

2.5

News and Social Media Coverage

News Sentiment
Heron Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Heron Therapeutics this week, compared to 2 articles on an average week.
Search Interest
22 people have searched for HRTX on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.
MarketBeat Follows
9 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Heron Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $260,650.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.40% of the stock of Heron Therapeutics is held by insiders.
Percentage Held by Institutions
81.77% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Heron Therapeutics are expected to grow in the coming year, from ($0.88) to ($0.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Heron Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Heron Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Heron Therapeutics has a P/B Ratio of 13.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Heron Therapeutics Stock (NASDAQ:HRTX)

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

HRTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HRTX Stock News Headlines

November 30, 2023 | seekingalpha.com

Why Heron Therapeutics Is A Compelling Buy Into 2024

November 19, 2023 | finance.yahoo.com

CEO & Director of Heron Therapeutics Craig Collard Buys 411% More Shares

December 6, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 17, 2023 | finanznachrichten.de

Heron Therapeutics, Inc.: Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

November 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Asensus Surgical (ASXC), Cue Health (HLTH) and Heron Therapeutics (HRTX)

November 15, 2023 | markets.businessinsider.com

Why Is Pain Treatment Focused Heron Therapeutics Stock Trading Higher Today?

November 15, 2023 | finance.yahoo.com

Q3 2023 Heron Therapeutics Inc Earnings Call

November 15, 2023 | finance.yahoo.com

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript

December 6, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 15, 2023 | finance.yahoo.com

Heron Therapeutics Inc (HRTX) Raises 2023 Sales Guidance and Projects Positive EBITDA in 2024

November 14, 2023 | finance.yahoo.com

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

November 14, 2023 | finance.yahoo.com

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

November 13, 2023 | markets.businessinsider.com

Heron Therapeutics is about to announce its earnings — here's what to expect

November 7, 2023 | finance.yahoo.com

Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023

October 29, 2023 | nypost.com

Philly motorcyclist filmed stomping on car windshield arrested after his employer tips off police

October 14, 2023 | thetimes.co.uk

The Boy and the Heron review — another Studio Ghibli masterpiece

August 15, 2023 | finanznachrichten.de

Heron Therapeutics, Inc.: Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

August 15, 2023 | finance.yahoo.com

Q2 2023 Heron Therapeutics Inc Earnings Call

August 15, 2023 | finance.yahoo.com

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Call Transcript

August 15, 2023 | finance.yahoo.com

Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say

August 15, 2023 | finance.yahoo.com

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

August 14, 2023 | finance.yahoo.com

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

August 8, 2023 | finance.yahoo.com

Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

August 3, 2023 | msn.com

Heron Therapeutics (HRTX) Price Target Decreased by 5.19% to 7.45

July 28, 2023 | msn.com

Heron Therapeutics: Restructuring Brings About A New Dawn

July 27, 2023 | benzinga.com

Director of Heron Therapeutics Makes $3.41M Buy

July 24, 2023 | nasdaq.com

Heron Therapeutics Announces Cost Reduction Plan - Quick Facts

See More Headlines

Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/23/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HRTX
CUSIP: N/A
CIK: 818033
Web: www.herontx.com
Phone: (858) 251-4400
Fax: 650-365-6490
Employees: 203
Year Founded: 1983

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $10.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +386.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-182,020,000.00
Net Margins: -97.45%
Pretax Margin: -97.45%
Return on Equity: -21,127.62%
Return on Assets: -53.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.43
Quick Ratio: 1.91

Sales & Book Value

Annual Sales: $107.67 million
Price / Sales: 2.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.11 per share
Price / Book: 13.09

Miscellaneous

Outstanding Shares: 150,070,000
Free Float: 140,468,000
Market Cap: $216.10 million
Optionable: Optionable
Beta: 1.51

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Craig Alexander Collard (Age 57)
CEO & Director
Ms. Ira Duarte (Age 54)
Executive VP & CFO
Ms. Lisa Peraza (Age 46)
VP & Chief Accounting Officer
Comp: $474.1k
Dr. Thomas B. Ottoboni Ph.D. (Age 64)
Chief Scientific Officer and Senior VP of Pharmaceutical & Translational Sciences
Mr. Ryan Craig
Vice President of Marketing
Mr. Sean T. Ristine (Age 53)
Senior Vice President of Human Resources
Dr. Chris M. Storgard (Age 57)
Chief Medical Officer
Mr. Robert Sullivan (Age 45)
Senior VP of Oncology Care Franchise & Commercial Operations
Dr. William P. Forbes Pharm. D. (Age 61)
Pharm.D., Executive VP & Chief Development Officer
Jeff Cohn
Executive Director, Assistant General Counsel & Assistant Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Heron Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings or view top-rated stocks.
What is Heron Therapeutics' stock price target for 2024?: 3 brokers have issued 1-year target prices for Heron Therapeutics' shares. Their HRTX share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 386.1% from the stock's current price.
View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts.
How have HRTX shares performed in 2023?: Heron Therapeutics' stock was trading at $2.50 at the start of the year. Since then, HRTX shares have decreased by 42.4% and is now trading at $1.44.
View the best growth stocks for 2023 here.
When is Heron Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our HRTX earnings forecast.
How were Heron Therapeutics' earnings last quarter?: Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08. The biotechnology company had revenue of $30 million for the quarter, compared to the consensus estimate of $27.24 million. Heron Therapeutics had a negative net margin of 97.45% and a negative trailing twelve-month return on equity of 21,127.62%. The company's revenue was up 44.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.54) EPS.
What ETFs hold Heron Therapeutics' stock?: ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Invesco Nasdaq Future Gen 200 ETF (QQQS).Simplify Propel Opportunities ETF (SURI).

What other stocks do shareholders of Heron Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).
Who are Heron Therapeutics' major shareholders?: Heron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Rubric Capital Management LP (18.98%), JW Asset Management LLC (1.71%), Tejara Capital Ltd (1.50%), Tejara Capital Ltd (1.50%), Adage Capital Partners GP L.L.C. (1.42%) and New York State Common Retirement Fund (0.78%). Insiders that own company stock include Adam Morgan, Craig A Collard, Craig A Johnson, David Leslie Szekeres, Ira Duarte, Kimberly Manhard, Waage Christian and William P Forbes.
View institutional ownership trends.
How do I buy shares of Heron Therapeutics?: Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Heron Therapeutics have any subsidiaries?: The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..
Read More

This page (NASDAQ:HRTX) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Heron Therapeutics Stock Price, News & Analysis (NASDAQ:HRTX)

Heron Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Heron Therapeutics Stock (NASDAQ:HRTX)

HRTX Stock Price History

HRTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

HRTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™